Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
Biogen Inc. (BIIB) Management presents at Leerink Global Healthcare Conference 2025 (Transcript)
Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...
BioSpace16d
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...
STAT17d
We’re reading about an FDA quality lab lease, Marty Makary’s confirmation hearing, and more
Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...
Frontiers17d
Mechanism of endogenous hormones regulating gallic acid biosynthesis during the development of buds and leaves in tea plant (Camellia sinensis)
2024). Although the accumulation of GA during the development of tea shoots and the regulation of plant hormones on GA biosynthesis in tea plants have been preliminarily confirmed, the regulation ...
JCN Newswire18d
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
BioWorld19d
Australia’s TGA rejects Eisai’s Leqembi again
Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...
Armed robbery in Revesby19d
TGA Confirms Decision To Not Register Lecanemab
In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the treatment of patients with Mild Cognitive Impairment (MCI) ...
MarketWatch22d
Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug
Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...
Utah Public Radio24d
Did a new Alzheimer's drug keep this patient's brain healthier for longer?
In 2020, Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Four years later, she and her husband, Ken, halted the treatment. Sue's ...
New Hampshire Public Radio25d
One woman's experience with the Alzheimer's drug Leqembi
NPR's Jon Hamilton has been talking to people who've taken these drugs, and today he has the story of one of the first patients to receive the drug now marketed as Leqembi. JON HAMILTON ...